Imipenem-Cilastatin Dosing
For adults with normal renal function, the standard dose of imipenem-cilastatin is 500 mg every 6 hours OR 1,000 mg every 8 hours intravenously, with dose reductions required when creatinine clearance falls below 90 mL/min. 1
Standard Adult Dosing (Normal Renal Function)
For patients with creatinine clearance ≥90 mL/min, three FDA-approved regimens exist 1:
- 500 mg every 6 hours (most common)
- 1,000 mg every 8 hours
- 1,000 mg every 6 hours (for severe infections)
The dose refers to the imipenem component; cilastatin is always given in a 1:1 ratio with imipenem.
Pediatric Dosing
Neonates and infants require weight-based dosing that varies by age and birth weight 2:
- Neonates 0-4 weeks, <1200g: 20 mg/kg every 18-24 hours
- Neonates ≤7 days, 1200-1500g: 40 mg/kg/day divided every 12 hours
- Neonates ≤7 days, >1500g: 50 mg/kg/day divided every 12 hours
- Neonates >7 days, >1500g: 75 mg/kg/day divided every 8 hours
- Infants <3 months: 100 mg/kg/day divided every 6 hours
- Infants ≥3 months and children: 60-100 mg/kg/day divided every 6 hours 2, 3
For drug-resistant tuberculosis in children, the dose is 15-25 mg/kg/dose given 3 times daily 4.
Renal Impairment Dosing
Dose reduction is mandatory when creatinine clearance drops below 90 mL/min 1. The pharmacokinetics differ significantly between imipenem and cilastatin in renal failure:
- Imipenem half-life: increases from 52 minutes (normal function) to 173 minutes (end-stage renal disease) 5
- Cilastatin half-life: increases from 54 minutes (normal function) to 798 minutes (end-stage renal disease) 5
Specific Renal Dosing Adjustments
For creatinine clearance <15 mL/min: Maximum dose should be limited to either 1,000 mg twice daily OR 500 mg four times daily 5. Patients should not receive imipenem-cilastatin unless hemodialysis is instituted within 48 hours 1.
For severe renal impairment (CrCl ~10 mL/min): 500 mg every 12 hours is well-tolerated and maintains therapeutic levels for 8-10 hours 6. This regimen does not cause imipenem accumulation but cilastatin levels stabilize after the third dose 6.
For hemodialysis patients: 500 mg every 12 hours is the most efficient schedule 7. Both drugs are removed by dialysis—imipenem half-life decreases from 4.8 to 2.45 hours, and cilastatin from 16.6 to 3.86 hours during dialysis 8. Administer supplemental doses after dialysis 5.
Mechanism of Renal Adjustment
The dramatic difference in cilastatin accumulation occurs because renal disease causes an 87% reduction in nonrenal clearance of cilastatin, while imipenem clearance remains more predictable 8. Cilastatin accumulation is clinically significant but generally well-tolerated at recommended doses 6.
Special Populations and Contexts
Non-Tuberculous Mycobacterial Disease
For NTM pulmonary disease in adults >50 kg: 1 g twice daily (intravenous), though 750 mg three times daily has also been used 9. For adults <50 kg, use 15 mg/kg twice daily 9.
Drug-Resistant Tuberculosis
Adults: 1,000 mg 3-4 times daily 4 Children: 15-25 mg/kg/dose, 3 times daily (imipenem component) 4
In reduced renal function for TB treatment: May reduce frequency of administration 4
Complicated Intra-Abdominal Infections (Pediatric)
60-100 mg/kg/day divided every 6 hours 3. Doses should be maximized if undrained abscesses may be present 3.
Critical Dosing Considerations
Augmented Renal Clearance
Patients with creatinine clearance ≥250 mL/min may require full dosing (1.25 g every 6 hours) to achieve adequate drug exposures 10. Standard dose adjustments based on prescribing information are insufficient in this population.
Hepatic Impairment
No dose adjustment is required for hepatic impairment alone 11. However, cilastatin clearance is reduced by impaired liver function, which may compound accumulation in patients with combined hepatic and renal dysfunction 12.
Elderly Patients
Pharmacokinetics in healthy elderly (65-75 years) with normal renal function for age are consistent with slight renal impairment, requiring no specific dosage alteration 13. However, age-related renal decline necessitates dose reduction based on measured creatinine clearance.
Administration Details
Infuse over 20-60 minutes depending on dose 13. Peak plasma levels after 20-minute infusion: 21-58 mcg/mL (500 mg dose) and 41-83 mcg/mL (1,000 mg dose) 13. Plasma levels decline to <1 mcg/mL within 4-6 hours 13.
Common Pitfalls
Do not use standard dosing in patients with CrCl <90 mL/min—this is the most critical error. The FDA label explicitly requires dose reduction at this threshold, not just in severe renal impairment 1.
Avoid in patients with CrCl <15 mL/min unless dialysis is planned within 48 hours 1. The accumulation of cilastatin in particular becomes problematic without renal replacement therapy.
Monitor for seizures in patients with CNS disorders, elderly patients, or those with renal impairment receiving excessive doses 14. While seizure risk is similar between imipenem and meropenem when dosed appropriately, improper dosing in renal failure significantly increases risk 14.
Remember that cilastatin protects against imipenem nephrotoxicity by inhibiting both renal dehydropeptidase-I AND organic anion transporters (OATs) 15. Never administer imipenem without cilastatin.